Cargando...
FOLFOXIRI plus Bevacizumab Versus FOLFOX plus Panitumumab for Metastatic Left‐Sided RAS/BRAF Wild‐Type Colorectal Cancer: Which “Side” Are You On?
This commentary focuses on the results of the study by Pietrantonio et al., which evaluated the clinical conundrum of triplet versus doublet chemotherapy in combination with targeted therapy for metastatic left‐sided RAS/BRAF wild‐type colorectal cancer and appears in this issue. Both FOLFOXIRI [flu...
Gardado en:
| Publicado en: | Oncologist |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley & Sons, Inc.
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8018293/ https://ncbi.nlm.nih.gov/pubmed/33539032 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13705 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|